[go: up one dir, main page]

AU2001289751A1 - Selective pde 2 inhibitors, used as medicaments for improving cognition - Google Patents

Selective pde 2 inhibitors, used as medicaments for improving cognition

Info

Publication number
AU2001289751A1
AU2001289751A1 AU2001289751A AU8975101A AU2001289751A1 AU 2001289751 A1 AU2001289751 A1 AU 2001289751A1 AU 2001289751 A AU2001289751 A AU 2001289751A AU 8975101 A AU8975101 A AU 8975101A AU 2001289751 A1 AU2001289751 A1 AU 2001289751A1
Authority
AU
Australia
Prior art keywords
medicaments
inhibitors
selective pde
improving cognition
cognition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001289751A
Inventor
Frank-Gerhard Boss
Martin Hendrix
Gerhard Konig
Ulrich Niewohner
Dagmar Schauss
Karl-Heinz Schlemmer
Rudy Schreiber
Franz-Josef Van Der Staay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122893A external-priority patent/DE10122893A1/en
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU2001289751A1 publication Critical patent/AU2001289751A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001289751A 2000-08-01 2001-07-19 Selective pde 2 inhibitors, used as medicaments for improving cognition Abandoned AU2001289751A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE10037411 2000-08-01
DE10037411.5 2000-08-01
DE10037411 2000-08-01
DE10122893 2001-05-11
DE10122893.7 2001-05-11
DE10122893A DE10122893A1 (en) 2000-08-01 2001-05-11 Selective PDE 2 inhibitors as medicines to improve perception
PCT/EP2001/008609 WO2002009713A2 (en) 2000-08-01 2001-07-19 Selective pde 2 inhibitors, used as medicaments for improving cognition

Publications (1)

Publication Number Publication Date
AU2001289751A1 true AU2001289751A1 (en) 2002-02-13

Family

ID=26006577

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001289751A Abandoned AU2001289751A1 (en) 2000-08-01 2001-07-19 Selective pde 2 inhibitors, used as medicaments for improving cognition

Country Status (7)

Country Link
US (1) US7022709B2 (en)
EP (1) EP1307201B1 (en)
JP (1) JP2004505054A (en)
AU (1) AU2001289751A1 (en)
CA (1) CA2417631A1 (en)
ES (1) ES2233685T3 (en)
WO (1) WO2002009713A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2002089808A1 (en) * 2001-05-09 2002-11-14 Bayer Healthcare Ag Novel use of 2-phenyl-substituted imidazotriazinones
CA2475879A1 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
NZ537076A (en) 2002-05-09 2007-06-29 Cytokinetics Inc Pyrimidinone compounds, compositions and methods
JP2005530785A (en) 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
AU2003265242A1 (en) 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003236527A1 (en) 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
DE10232113A1 (en) 2002-07-16 2004-01-29 Bayer Ag Medicinal products containing vardenafil hydrochloride trihydrate
EP1537089A4 (en) 2002-07-23 2008-04-16 Cytokinetics Inc Compounds compositions and methods
DE10238723A1 (en) 2002-08-23 2004-03-11 Bayer Ag Phenyl substituted pyrazolyprimidines
DE10238722A1 (en) 2002-08-23 2004-03-11 Bayer Ag Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives
DE10238724A1 (en) 2002-08-23 2004-03-04 Bayer Ag New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance
AU2003277079A1 (en) 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
JP2006525966A (en) * 2003-05-09 2006-11-16 バイエル・ヘルスケア・アクチェンゲゼルシャフト 6-cyclylmethyl- and 6-alkylmethyl substituted pyrazolopyrimidines
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE102004004142A1 (en) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
DE10320785A1 (en) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-arylmethyl substituted pyrazolopyrimidines
DE10328479A1 (en) 2003-06-25 2005-01-13 Bayer Ag 6-arylamino-5-cyano-4-pyrimidinones
WO2005021037A1 (en) * 2003-08-28 2005-03-10 Altana Pharma Ag Composition comprising a pulmonary surfactant and a pde2 inhibitor
WO2005061460A1 (en) 2003-12-08 2005-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
DE102004001873A1 (en) 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
JP2009512711A (en) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Regulation of neurogenesis by PDE inhibition
JP2009513672A (en) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド GABA receptor-mediated regulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
MX2009002496A (en) 2006-09-08 2009-07-10 Braincells Inc Combinations containing a 4-acylaminopyridine derivative.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
AP2011005672A0 (en) 2008-09-08 2011-04-30 Boehringer Ingelheim Int Pyrazolopyrimidines and their use for the treatment of CNS disorders.
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2010112437A1 (en) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
TW201118099A (en) * 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
NZ603725A (en) 2010-08-12 2015-04-24 Boehringer Ingelheim Int 6-cycloalkyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JP6157455B2 (en) 2012-04-25 2017-07-05 武田薬品工業株式会社 Nitrogen-containing heterocyclic compounds
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
WO2014142255A1 (en) 2013-03-14 2014-09-18 武田薬品工業株式会社 Heterocyclic compound
JP6427491B2 (en) 2013-07-03 2018-11-21 武田薬品工業株式会社 Heterocyclic compounds
JP6411342B2 (en) 2013-07-03 2018-10-24 武田薬品工業株式会社 Amide compounds
JP6696904B2 (en) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． Formulations and pharmaceutical compositions
KR102557603B1 (en) 2014-12-06 2023-07-19 인트라-셀룰라 써래피스, 인코퍼레이티드. Organic compounds
JP6608933B2 (en) 2014-12-06 2019-11-20 イントラ−セルラー・セラピーズ・インコーポレイテッド Organic compounds
WO2017000276A1 (en) * 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
AU2017388054B2 (en) 2016-12-28 2022-03-24 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors
CN111051308A (en) 2017-06-08 2020-04-21 默沙东公司 Pyrazolopyrimidine PDE9 inhibitors
AU2018373258B2 (en) 2017-11-27 2023-03-02 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as PDE1 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3816995A1 (en) * 1988-05-19 1989-11-23 Hoechst Ag USE OF PYRIMIDO- (6,1-A) -ISOCHINOLIN-4-ON-DERIVATIVES AND MEDICAL PREPARATIONS BASED ON THESE COMPOUNDS
DE19541264A1 (en) * 1995-11-06 1997-05-07 Bayer Ag Purin-6-one derivatives
DE19709877A1 (en) 1997-03-11 1998-09-17 Bayer Ag 1,5-dihydro-pyrazolo [3,4-d] pyrimidinone derivatives
DE19838705A1 (en) * 1998-08-26 2000-03-02 Bayer Ag New dihydro- (1,2,3) -triazolo- [4,5-d] pyrimidin-7-ones
WO2000024745A1 (en) * 1998-10-23 2000-05-04 Pfizer Limited PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
CA2395410A1 (en) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Triazolotriazinones and the use thereof
US6803365B2 (en) * 1999-12-24 2004-10-12 Bayer Aktlengesellschaft Imidazo[1,3,5]triazinones and the use thereof
US6777416B2 (en) * 1999-12-24 2004-08-17 Bayer Aktiengesellschaft Isoxazolo pyrimidinones and the use thereof

Also Published As

Publication number Publication date
JP2004505054A (en) 2004-02-19
ES2233685T3 (en) 2005-06-16
EP1307201B1 (en) 2004-11-24
US20020132754A1 (en) 2002-09-19
US7022709B2 (en) 2006-04-04
WO2002009713A2 (en) 2002-02-07
CA2417631A1 (en) 2003-01-29
WO2002009713A3 (en) 2002-07-18
EP1307201A2 (en) 2003-05-07

Similar Documents

Publication Publication Date Title
AU2001289751A1 (en) Selective pde 2 inhibitors, used as medicaments for improving cognition
AU2002224927A1 (en) Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
AU2002222293A1 (en) Pyrazolo(3,4-c)pyridines as gsk-3 inhibitors
HUP0301742A3 (en) Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
AU6383101A (en) Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them
AU2002221753A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
AU2001241056A1 (en) Spiro compounds, process for preparing the same and use thereof as drugs
AU2001242364A1 (en) Process for the epoxidation of olefins
AU2000272858A1 (en) Pharmaceutical composition for treating hyperhomocysteinaemia caused by medicaments
AU2001292331A1 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
AU2001292331A2 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
AU2001273762A1 (en) Process for the preparation of (r)-2-alkyl-3-phenyl-1-propanols
AU2002241211A1 (en) Imidazo-triazine derivatives as pde 5 inhibitors
AU2002210632A1 (en) Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same
AU2000254308A1 (en) Pyrazolopyrimidinone derivatives, process for their preparation and their use
AU2002306687A1 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
AU2001258200A1 (en) Synthetic derivatives of lunularic acid, medicaments containing said compounds, method for producing the lunularic acid derivatives and the use thereof
AU4884701A (en) Malonanilic acid derivatives, medicinal compositions containing the same and usethereof
HK1053103A1 (en) 5-amino-1-pentene-3-ol substituted derivatives
AU2001235448A1 (en) Process for the epoxidation of olefins
AU2001252254A1 (en) 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparationthereof and use thereof
AU5462901A (en) Process for the preparation of (pyridinylidene)-phthalides
AU2001241042A1 (en) Process for the preparation of hydrazine derivatives
AU2002243394A1 (en) Aryloxy piperidinyl derivatives for the treatment of depression
HUP0000920A3 (en) Pde4 inhibitor isoquinolinylidene derivatives, process for their preparation and medicaments containing them